According to a new report by Polaris Market Research, the global pharmaceutical contract development & manufacturing organization (CDMO) market was valued at USD 192.19 billion in 2024 and is projected to reach USD 418.65 billion by 2034, expanding at a CAGR of 8.11% over the forecast period. Growth is underpinned by rising R&D expenditure to expand product pipelines, increasing chronic disease burden, and accelerating outsourcing of complex biologics manufacturing across key therapeutic areas.
What Is Driving Pharmaceutical CDMO Market Growth?
Demand is climbing as escalating R&D spending converges with the rising global burden of chronic disease. Pharmaceutical and biotech firms are prioritizing speed-to-market and capital efficiency, pushing CDMO adoption across small molecule and biologics manufacturing. Polaris analysts note that the largest 50 pharmaceutical companies together spent USD 167 billion on R&D in 2022 — up nearly 60% over the prior decade — positioning the small molecule segment for sustained growth through 2034, with large pharmaceutical companies emerging as the largest end-use contributor and large molecule biologics posting the fastest incremental gains.
Key Trends Shaping the Pharmaceutical CDMO Industry
Process Development Platforms for Small Molecule APIs
CDMOs are investing in proprietary platforms to differentiate on speed and flexibility. In May 2025, Lonza unveiled its Design2Optimize platform for optimizing process development and manufacturing of small molecule APIs, reflecting the industry trend toward more efficient, technology-driven CDMO service models.
Browse Insights:
Sterile Manufacturing Capacity Consolidation
Facility acquisitions continue to expand end-to-end service capacity. In June 2025, Thermo Fisher Scientific expanded its collaboration with Sanofi through the acquisition of Sanofi's sterile manufacturing facility in Ridgefield, New Jersey, complementing its national fill-finish network and boosting its Accelerator Drug Development 360° platform.
National Biomanufacturing Policy Support
Government-backed initiatives are reshaping regional CDMO competitiveness. In August 2024, India's Union Cabinet cleared the BioE3 Policy aimed at establishing the country as a global biotech manufacturing hub, targeting high-performance biomanufacturing, export growth, and employment generation — a regulatory landscape shift accelerating Asia Pacific's CDMO expansion.
Market Segmentation: Breaking Down the Pharmaceutical CDMO Market
Polaris segments the pharmaceutical CDMO market by type, product, service, workflow, therapeutic area, end use, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.
By Type
The small molecule segment held the highest share in 2024, driven by extensive use in generic medications and oral drugs that remain the most prevalent prescription volumes worldwide. Large molecules are expected to post robust growth as biologics, biosimilars, and cell and gene therapy pipelines expand.
By Product
The API segment accounted for a major share in 2024, as pharmaceutical companies depend on CDMOs for large-scale, compliant, and economical active pharmaceutical ingredient manufacturing. The drug product segment is anticipated to grow steadily, driven by increasing formulation development, packaging, and finishing demand.
By Service
Contract manufacturing led the market share in 2024, driven by rising production outsourcing to minimize capital investment and comply with regulations. Contract development is anticipated to grow robustly, led by early-stage formulation and analytical development services.
By Therapeutic Area
Oncology led the market in 2024 due to growth in targeted therapy and biologic development for cancer treatment. Infectious diseases are anticipated to grow rapidly, driven by continued innovation in personalized and chronic disease treatments.
Regional Outlook: Where Is Pharmaceutical CDMO Demand Growing Fastest?
North America dominated the CDMO market in 2024, fueled by the superior presence of large pharmaceutical and biotech players outsourcing to save money and speed up time-to-market, with the U.S. leading on stringent regulatory requirements and increasing collaboration with certified CDMOs. Asia Pacific is expected to expand rapidly, propelled by international CDMOs expanding their bases in China and India, with India leading the region through government support and cost-effective manufacturing solutions. Europe held substantial market share, propelled by a strong regulatory framework and growing demand for contract-based development of Advanced Therapy Medicinal Products (ATMPs).
Competitive Landscape: Leading Pharmaceutical CDMO Companies
Key players profiled in the report include Lonza Group AG, Catalent, Inc., Samsung Biologics Co., Ltd., WuXi AppTec Co., Ltd., Thermo Fisher Scientific Inc. (Patheon Inc.), and Boehringer Ingelheim International GmbH, who are focusing on biologics manufacturing investment, innovative formulation technologies, and regulatory-approved infrastructure to strengthen market position across the small molecule and large pharmaceutical company segments outlined above. Recent moves include Polpharma Biologics' August 2025 global licensing agreement with Fresenius Kabi for a proposed vedolizumab biosimilar, and Thermo Fisher's April 2025 enhanced CHO K-1 cell line that shortened IND timelines from 13 to nine months.
Why It Matters for Buyers Evaluating Market Entry
For stakeholders researching outsourced drug manufacturing capacity, this report benchmarks pharmaceutical CDMO market share, segment-level pricing, and forecast data — by type, product, service, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing CDMO vendors, investors sizing entry points in biologics manufacturing, and strategy teams tracking large molecule outsourcing as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.
More Trending Latest Reports By Polaris Market Research:
leading-top-10-companies-in-drone-batteries-market-to-know-in-2025